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Purpose. Neutrophil-dominated airway inflammation is a key feature of progressive lung damage in cystic fibrosis (CF). Thus,
reducing airway inflammation is amajor goal to prevent lung damage in CF. However, current anti-inflammatory drugs have shown
several limits. PI3K𝛾 plays a pivotal role in leukocyte recruitment and activation; in the present study we determined the effects
of genetic deletion and pharmacologic inhibition of PI3K𝛾 on airway inflammation and structural lung damage in a mouse model
of CF lung disease. Methods. 𝛽ENaC overexpressing mice (𝛽ENaC-Tg) were backcrossed with PI3K𝛾-deficient (PI3K𝛾KO) mice.
Tissue damage was assessed by histology andmorphometry and inflammatory cell number was evaluated in bronchoalveolar lavage
fluid (BALF). Furthermore, we assessed the effect of a specific PI3K𝛾 inhibitor (AS-605240) on inflammatory cell number in BALF.
Results. Genetic deletion of PI3K𝛾decreasedneutrophil numbers inBALFof PI3K𝛾KO/𝛽ENaC-Tgmice, and thiswas associatedwith
reduced emphysematous changes. Treatment with the PI3K𝛾 inhibitor AS-605240 decreased the number of neutrophils in BALF of
𝛽ENaC-Tg mice, reproducing the effect observed with genetic deletion of the enzyme. Conclusions. These results demonstrate the
biological efficacy of both genetic deletion and pharmacological inhibition of PI3K𝛾 in reducing chronic neutrophilic inflammation
in CF-like lung disease in vivo.
1. Introduction
Cystic fibrosis (CF), the most common genetic disease in
Caucasian populations, results from mutations in a sin-
gle gene encoding for 1480 residues transmembrane gly-
coprotein, the cystic fibrosis transmembrane conductance
regulator (CFTR), that regulates cAMP-mediated chloride
conductance at the apical surface of secretory epithelia [1, 2].
Impaired CFTR-mediated secretion of Cl- and bicarbonate
results in dehydration and acidification of the airway surface
liquid, which in turn causes impaired mucociliary clearance
and bacterial killing. These defects trigger a progressive lung
disease characterized by airway mucus obstruction, chronic
neutrophilic inflammation, bacterial infection, and structural
lung damage that remains the major cause of morbidity and
mortality in patients with CF [3].
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A growing number of in vitro and in vivo studies support
the notion that chronic neutrophilic inflammation with the
release of damaging neutrophil products, such as neutrophil
elastase, constitutes a key risk factor in early structural lung
damage and lung function decline in CF [4–6]. Neutrophilic
airway inflammation is augmented after onset of chronic
bacterial infection with Pseudomonas aeruginosa and other
pathogens. In this context, the inflammatory response in the
CF lung is nonresolving and self-perpetuating, and a vicious
cycle of neutrophilic inflammation, noxiousmediator release,
and overwhelmed defenses amplifies inflammation, perpet-
uates infection and contributes to irreversible lung damage
and disease progression [7–9]. Therefore, anti-inflammatory
therapy, combined with antibiotic therapy, appears crucial
to prevent chronic lung damage. However, traditional ther-
apeutic strategies, as well as more recently studied anti-
inflammatory drugs, have shown several limitations and
limited clinical benefit [8–10]. Clearly, novel approaches have
to be undertaken to provide effective anti-inflammatory
therapy to CF patients. One possibility is to interfere with
leukocyte trafficking into CF airways. Trafficking of leuko-
cytes is controlled by chemotactic factors which bind to het-
erotrimeric G-protein-coupled receptors (GPCR) and trigger
a complex set of signaling pathways inside the cell involving
the generation of second messengers like phosphoinositides.
Phosphoinositides are substrates of the phosphoinositide 3-
kinases (PI3Ks), enzymes that catalyze the phosphorylation
of the phosphatidylinositol at the 3rd position of the inositol
ring. PI3Ks modulate a wide number of cellular functions
such as proliferation and survival, cytoskeletal remodeling,
andmembrane trafficking and represent importantmediators
in the signaling cascade leading to the initiation of the
inflammatory response [11–14]. PI3Ks can be divided in three
classes (I, II, and III) based on their biochemical properties.
Leukocytes express all four known isoforms of class I PI3Ks,
namely, PI3K 𝛼, 𝛽, 𝛿, and 𝛾 [14]; nonetheless PI3K𝛾 plays
a fundamental role in leukocyte migration and function
by acting as a chemokine sensor and regulating neutrophil
oxidative burst, T cell proliferation, and mast degranulation.
We therefore hypothesized that PI3K𝛾 plays a pivotal role in
mediating leukocyte recruitment and activation andmay thus
represent a potential target for anti-inflammatory treatment
to reduce neutrophilic airway inflammation and lung damage
in CF. To test this hypothesis, we used transgenic mice with
airway-specific overexpression of the epithelial Na+ channel
(ENaC) and determined the effects of genetic deletion and
pharmacologic inhibition of PI3K𝛾 [15–17].
2. Materials and Methods
2.1. Mice. PI3K𝛾WT/𝛽ENaC-Tg (𝛽ENaC-Tg) [15–18] and
PI3K𝛾-deficient (PI3K𝛾KO, Harlan, Italy) mice on the
C57BL/6 background were intercrossed to generate 𝛽ENaC-
Tg/PI3K𝛾KO mice. All experiments were performed in 7-
to 8-week-old adult mice. 𝛽ENaC-Tg, PI3K𝛾KO, PI3K𝛾KO/
𝛽ENaC-Tg, and wild-type (PI3K𝛾WT) mice were housed in
a pathogen-free animal facility at the Istituto per la Ricerca e
la Cura del Cancro, University of Turin, in accordance with
the Institutional Animal Welfare Guidelines and Italian
legislation. The animal study protocols were reviewed and
approved by the Institutional Animal Ethics Committee of
the Istituto per la Ricerca e la Cura del Cancro, University
of Turin, Turin, Italy, and performed according to the Insti-
tutional Animal Welfare Guidelines and Italian legislation.
2.2. Assessment of Inflammatory Cells in Bronchoalveolar
Lavage. Inflammatory cell numbers were assessed in the
broncoalveolar fluid (BALF) of PI3K𝛾WT mice and of
PI3K𝛾WT/𝛽ENaC-Tg, PI3K𝛾KO, and PI3K𝛾KO/𝛽ENaC-Tg
mice. Briefly, mice from each genotype were sacrificed and
BALF was then collected by lavaging lungs in situ with 3 ×
1-mL volumes of PBS. After centrifugation of the BALFs,
cell pellets, in 500𝜇L of RPMI medium, were deposited
onto glass slides using a Cytospin Cytocentrifuge. Slides
were then stained using theDiff-Quick system (MICROPTIC
S.L., Spain) and a differential cell count was performed as
previously described [19]. In addition, BALF inflammatory
cells were also analyzed in mice treated with the PI3K𝛾
inhibitor AS-605240 [5-(quinoxalin-6-ylmethylidene)-1,3-
thiazolidine-2,4-dione] (Sigma, Germany). PI3K𝛾WT and
PI3K𝛾WT/𝛽ENaC-Tg mice were treated once daily for 3 days
with the AS-605240 by intraperitoneal injection of 10mg/kg
of the drug or vehicle (0.5% carboxymethyl cellulose, 0.25%
Tween) alone.
2.3. Lung Histology and Morphometry. Animals of each
group were sacrificed under anaesthesia with pentobarbital
(60mg/Kg) and the lungs fixed intratracheally with buffered
formalin (5%) at a constant pressure of 20 cm H
2
O. Lung
volume (𝑉) was measured by water displacement according
to Scherle [20]. Sagittal sections of each pair of lungs were
cut and stained with haematoxylin/eosin. The slides were
coded to prevent bias. Morphometric evaluations included
determination of the average interalveolar distance (mean
linear intercept: Lm) [21] and internal surface area (ISA)
estimated by the Lm method at postfixation lung volume
by the formula 4𝑉/Lm, where 𝑉 is the postfixation lung
volume [22]. For the determination of the Lm for each
pair of lungs, 40 histological fields were evaluated both
vertically and horizontally. The development of goblet cell
metaplasia was evaluated by periodic acid-Schiff reaction
(PAS) according to standard histological protocols [23]. The
total number of cells, as well as the percentage of PAS-positive
cells, was determined. The number of cells in airways that
demonstrated PAS staining was determined by examining
eight intrapulmonary airways per section and counting at
least 3,000 cells/section. Data were reported as the percentage
of positive cells per total cells.
2.4. Statistical Analysis. Statistical analyses were performed
using one-way analysis of variance. Survival curves were
compared using Kaplan-Meier log rank analysis. 𝑃 < 0.05
was considered statistically significant and “𝑛” represents
the number of mice in each experimental group. Data are
expressed as mean ± SD.
Mediators of Inflammation 3
3. Results
3.1. Genetic Deletion of PI3K𝛾 Reduces Neutrophilic Air-
way Inflammation and Mortality in 𝛽ENaC-Tg Mice. As
observed in previous studies, 𝛽ENaC-Tg (PI3K𝛾WT/𝛽ENaC-
Tg; Figure 1(a)) mice on the C56BL/6J background exhibited
a spontaneous mortality of ∼23% [18, 24]. Deletion of PI3K𝛾
had no effect on survival in wild-type mice; however, in
the presence of the 𝛽ENaC transgene (PI3K𝛾KO/𝛽ENaC-Tg),
PI3K𝛾 loss significantly reduced themortality by ∼50%, since
at 60 days the survival rate is more than 85% (𝑃 < 0.05,
Figure 1(a)).
To determine the effect of genetic deletion of PI3K𝛾 on
airway inflammation, we compared inflammatory cell num-
bers in BAL fluid from surviving PI3K𝛾WT/𝛽ENaC-Tg and
PI3K𝛾KO/𝛽ENaC-Tg mice. As expected, in homozygous
PI3K𝛾WT and PI3K𝛾KO control mice, neutrophils were
rarely detected in the BALF (Figure 1(b)) as well as in
the airways lumen (Figure 1(c)). The number of neu-
trophils, in BALF and in the airways lumen, was markedly
elevated in PI3K𝛾WT/𝛽ENaC-Tg mice (Figures 1(b) and
1(c)). On the contrary, the absence of PI3K𝛾 expres-
sion in PI3K𝛾KO/𝛽ENaC-Tg mice led to a large reduction
of neutrophil recruitment into the lung if compared to
PI3K𝛾WT/𝛽ENaC-Tg mice (Figure 1(b)). Nonetheless, dele-
tion of PI3K𝛾 did not affect macrophage and lympho-
cyte recruitment as no differences were detected between
PI3K𝛾KO/𝛽ENaC-Tg and PI3K𝛾WT/𝛽ENaC-Tgmice in BALF
(Figures 1(d) and 1(e)).
3.2. Genetic Deletion of PI3K𝛾 Reduces Structural Lung
Damage in 𝛽ENaC-Tg Mice. Chronic inflammation, in
PI3K𝛾WT/𝛽ENaC-Tg mice, triggers emphysema with distal
airspace enlargement and alveolar destruction resulting in
reduced lung tissue density and increased lung compliance [6,
17, 19]. To assess the protective effects of the genetic deletion
of PI3K𝛾 on emphysema-like changes in PI3K𝛾KO/𝛽ENaC-
Tg mice, we determined the averaged interalveolar distance
(mean linear intercept, Lm) and the internal surface area
(ISA) estimated by the Lm method at postfixation lung
volume. ISA and Lm were not altered in the lungs of
controls PI3K𝛾WT and PI3K𝛾KO mice (Figures 2(a) and 2(b)),
and morphological analysis showed a well-fixed normal
parenchyma with normal airways (data not shown). As
expected from previous studies [6, 17, 19], PI3K𝛾WT/𝛽ENaC-
Tg mice lungs showed significant emphysematous changes
(Figures 2(a)–2(c)) while the genetic deletion of PI3K𝛾 in
PI3K𝛾KO/𝛽ENaC-Tg mice resulted in a significant reduction
of the degree of emphysema, as assessed by both morpho-
metric analyses (ISA: 𝑃 < 0.0002 versus PI3K𝛾WT/𝛽ENaC-
Tg mice; Lm: 𝑃 < 0.0003 versus PI3K𝛾WT/𝛽ENaC-Tg mice;
Figures 2(a) and 2(b)) and morphology (Figure 2(c)).
In addition to neutrophilic inflammation, goblet cell
metaplasia and mucus obstruction were a common fea-
ture of the airways of adult PI3K𝛾WT/𝛽ENaC-Tg mice
[19]. Since neutrophil products, such as neutrophil elastase,
have been implicated in goblet cell metaplasia and mucin
hypersecretion in CF [25, 26], we assessed the effects of
genetic deletion of PI3K𝛾 on goblet cell metaplasia. Goblet
cells were not observed in PI3K𝛾WT and PI3K𝛾KO mice;
in PI3K𝛾KO/𝛽ENaC-Tg mice, the goblet cell metaplasia
appeared reduced compared to PI3K𝛾WT/𝛽ENaC-Tg mice;
however, this difference was not statistically significant, based
on the variability and the number of mice included in our
studies (data not shown).
3.3. Pharmacological Inhibition of PI3K𝛾 Reduces Neutrophilic
Airway Inflammation in 𝛽ENaC-Tg Mice. Next we tested
effects of pharmacological inhibition of PI3K𝛾 by using the
inhibitor AS-605240 on airway inflammation in 𝛽ENaC-Tg
mice. Treatment of 𝛽ENaC-Tg mice with AS-605240 but not
with vehicle alone reduced neutrophil infiltrates in BALF of
𝛽ENaC-Tg mice (Figure 3(a)). In contrast, as observed in
PI3K𝛾KO/𝛽ENaC-Tg mice, the PI3K𝛾 inhibitor had no effect
on the recruitment of macrophages or lymphocytes into the
lung (Figures 3(b) and 3(c)).
4. Discussion
Progressive lung disease is the major cause of morbidity
and mortality in CF and is characterized by chronic airway
infection and associated airway inflammation leading to
irreversible lung destruction and early death [1–3]. Accu-
mulating evidences suggest that CFTR dysfunction impairs
mucociliary clearance and bacterial killing as crucial innate
defense mechanisms of the lung leading to chronic bacterial
infection and nonresolving inflammation in CF airways [3].
Themain feature of airway inflammation in CF is a persistent
influx of neutrophils that release a variety of oxidants and
granule-associated enzymes, thus contributing to the devel-
opment of lung injury and to the chronicity of pulmonary
infection [7–9]. Repeated episodes of exacerbation of chronic
infection and inflammation occur during the natural history
of the disease, further increasing the structural damage in
the CF lung [27, 28]. Therefore, anti-inflammatory therapy,
combined with antibiotic therapy, offers a rational approach
to prevent chronic lung damage. However, current anti-
inflammatory drugs have shown several limits. The use of
oral corticosteroids has been limited by severe adverse effects
and studies using inhaled corticosteroids in CF have not been
particularly successful [8, 9]. In addition, nonsteroidal anti-
inflammatory drugs, such as ibuprofen, although revealing
beneficial effects in younger CF patients [29], are difficult to
dose and thus are not widely used [30]. Likewise, a phase
3 study of the LTB
4
receptor antagonist BIIL 284 had been
stopped due to adverse effects in the treatment group [31].
An alternative approach to decrease chronic inflammation is
to use a more targeted anti-inflammatory therapy directed at
reducing neutrophil trafficking in theCF lung. In this context,
class I PI3K member, PI3K𝛾, has been demonstrated to play
a pivotal role in mediating leukocyte recruitment and acti-
vation into sites of inflammation [11]. Therefore PI3K𝛾 may
represent an innovative and appropriate target to interfere
with the excessive neutrophil-mediated inflammation and
damage in CF. Of note, recently developed small-molecule
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Figure 1: Continued.
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Figure 1: Effect of genetic deletion of PI3K𝛾 on mortality and airway inflammation in 𝛽ENaC-Tg mice. (a) Survival curves for the different
groups of mice studied (𝑃 < 0.05). (b) Neutrophil numbers were assessed in BALF of PI3K𝛾WT, PI3K𝛾WT/𝛽ENaC-Tg, PI3K𝛾KO, and
PI3K𝛾KO/𝛽ENaC-Tg mice. Neutrophils are expressed as cell numbers per mL of BALF (𝑛 = 10 mice for each group). Comparison between
the different groups was performed by one-way analysis of variance. ∗∗∗𝑃 < 0.001 PI3K𝛾WT versus PI3K𝛾WT/𝛽ENaC-Tg and ∗∗∗𝑃 <
0.001 PI3K𝛾WT/𝛽ENaC-Tg versus PI3K𝛾KO/𝛽ENaC-Tg. (c) Immunofluorescent detection of neutrophils in lung tissues of PI3K𝛾WT/𝛽ENaC-
Tg, PI3K𝛾KO, and PI3K𝛾KO/𝛽ENaC-Tg mice. Neutrophils were stained by using monoclonal rat antibodies to neutrophils (clone 7/4, Acris)
and nuclei with DAPI. (d) Lymphocyte numbers were assessed in BALF of PI3K𝛾WT, PI3K𝛾WT/𝛽ENaC-Tg, PI3K𝛾KO, and PI3K𝛾KO/𝛽ENaC-
Tg mice. Lymphocytes are expressed as number of cells per mL of BALF (𝑛 = 10 mice for each group) ∗𝑃 < 0.05 PI3K𝛾WT versus
PI3K𝛾WT/𝛽ENaC-Tg and ∗∗𝑃 < 0.01 PI3K𝛾KO versus PI3K𝛾KO/𝛽ENaC-Tg. (e) Macrophage numbers were assessed in BALF of PI3K𝛾WT,
PI3K𝛾WT/𝛽ENaC-Tg, PI3K𝛾KO, and PI3K𝛾KO/𝛽ENaC-Tg mice. Macrophages are expressed as number of cells per mL of BALF (𝑛 = 10mice
for each group). ∗𝑃 < 0.05 PI3K𝛾WT versus PI3K𝛾WT/𝛽ENaC-Tg and ∗∗𝑃 < 0.01 PI3K𝛾KO versus PI3K𝛾KO/𝛽ENaC-Tg.
PI3K𝛾 inhibitors were shown to be effective in suppressing
joint inflammation in mouse models of rheumatoid arthri-
tis [32]. In the present study we evaluated the effects of
genetic deletion and pharmacologic inhibition of PI3K𝛾
in the 𝛽ENaC-Tg mouse as a model of CF lung disease
[15, 16, 33]. Such model phenocopies the airway surface
dehydration and mucociliary dysfunction characteristic of
CF airways. 𝛽ENaC-Tg mice develop spontaneous CF-like
lung disease with early onset goblet cell metaplasia and
airway mucus obstruction, reduced bacterial clearance, and
chronic neutrophilic inflammation triggering emphysema-
like structural lung damage [15, 17, 34, 35]. Genetic deletion
of PI3K𝛾 resulted in decreased neutrophil numbers in BALF
of PI3K𝛾KO/𝛽ENaC-Tg mice, and reduced neutrophilia was
associated with reduced emphysematous changes in these
mice. Taken together, these data support an important role
of PI3K𝛾 for transmigration of neutrophils from the blood
into the airway lumen and a crucial role of neutrophilic
airway inflammation in the in vivo pathogenesis of lung
damage. Several leukocyte-derived proteases including neu-
trophil elastase have been shown to cause emphysema in
mice [36–38]. Furthermore, previous studies demonstrated
that overexpression of several proinflammatory mediators
in genetically modified mice induces an imbalance in the
pulmonary protease/antiprotease system and emphysema
in these mice [39, 40]. Thus, it is likely that neutrophil-
dominated chronic pulmonary inflammation and the dis-
ruption of protease/antiprotease balance contribute to the
development of emphysema in PI3K𝛾WT/𝛽ENaC-Tg mice.
Neutrophil elastase (NE) is the major product of activated
neutrophils and has been implicated in the pathogenesis
of key features of CF lung disease, such as chronic airway
inflammation, mucus hypersecretion, goblet cell metaplasia,
and structural damage [41–47]. We hypothesize that deletion
of PI3K𝛾 decreases lung damage through the reduction of
neutrophilic inflammation and neutrophil-associated active
elastase. Consistently, a recent study demonstrated that NE
activity is increased at the surface of airway neutrophils
in PI3K𝛾WT/𝛽ENaC-Tg mice and patients with CF [6] and
that genetic deletion of NE results in a significant reduction
of emphysema-like changes in PI3K𝛾WT/𝛽ENaC-Tg mice,
suggesting that NE is implicated in emphysema associated
with chronic neutrophilic airway inflammation in vivo.
Recently, selective PI3K𝛾 inhibitors have been devel-
oped and investigated in different mouse models of chronic
inflammation [48–51]. Therefore, we evaluated the efficacy
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Figure 2:Genetic deletion of PI3K𝛾 decreases emphysema in𝛽ENaC-Tgmice. Mouse lungs were fixed in 4% formalin and embedded in paraffin
and 5 𝜇m sections were stained with hematoxylin/eosin; assessment of emphysema included the internal surface area (ISA) at postfixation
lung volume and the morphometric assessment of the average inter-alveolar distance (mean linear intercept: Lm). (a) ISA and (b) Lm from
8-week-old wild type (PI3K𝛾WT), 𝛽ENaC-Tg, PI3K𝛾KO, and PI3K𝛾KO/𝛽ENaC-Tg mice (𝑛 = 8–10 mice for each group). Comparison among
groups was performed using one-way analysis of variance. (a) ∗𝑃 < 0.05 PI3K𝛾WT versus PI3K𝛾WT/𝛽ENaC-Tg, ∗∗𝑃 < 0.01 PI3K𝛾KO versus
PI3K𝛾WT/𝛽ENaC-Tg, ∗∗∗𝑃 < 0.001 PI3K𝛾WT/𝛽ENaC-Tg versus PI3K𝛾KO/𝛽ENaC-Tg; (b) ∗∗𝑃 < 0.01 PI3K𝛾WT versus PI3K𝛾WT/𝛽ENaC-Tg,
and 𝑃 < 0.01 PI3K𝛾KO versus PI3K𝛾WT/𝛽ENaC-Tg, ∗∗∗𝑃 < 0.001 PI3K𝛾WT/𝛽ENaC-Tg versus PI3K𝛾KO/𝛽ENaC-Tg mice. (c) Representative
histological sections from the lung of 8-week-old 𝛽ENaC-Tg mousee (left) showing evident areas of emphysema and PI3K𝛾KO/𝛽ENaC-Tg
(right) mouse showing a focal areas of mild emphysema. Haematoxylin and eosin stain. Original magnification ×40.
of the PI3K𝛾 inhibitor AS-605240 on airway inflammation
in 𝛽ENaC-Tg mice; we decided to use AS-605240 for its
well characterized in vivo profile of efficacy and selec-
tivity, indicated by the so far largest number of reports
of pharmacological PI3K𝛾 inhibition in mice [48–53]. We
showed that treatment with the PI3K𝛾 inhibitor decreased
the number of neutrophils in BALF of 𝛽ENaC-Tg mice, thus
reproducing the effect observed with the genetic deletion
of PI3K𝛾. Several technical problems limit the assessment
of the increased PI3K𝛾 activity in 𝛽ENaC mice; however,
the findings that PI3K𝛾WT/𝛽ENaC-Tg inflamed lungs have
more leukocytes than PI3K𝛾KO/𝛽ENaC-Tg controls are an
indirect indication of increased PI3K𝛾 activity in these mice.
Taken together, our data demonstrate the biological efficacy
of both genetic deletion and pharmacological inhibition of
PI3K𝛾 in reducing chronic neutrophilic inflammation in CF-
like lung disease in vivo.
Whereas blockade of PI3K𝛾 activity by small-molecule
inhibitors may represent a valid approach to modulate
excessive leukocyte accumulation in inflamed tissues where
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Figure 3: Pharmacological inhibition of PI3K𝛾 decreases neutrophilic airway inflammation in 𝛽ENaC-Tg mice. Neutrophils (a), lymphocytes
(b), and macrophages (c) numbers were determined in BAL fluid of control (WT/Vehicle) and 𝛽ENaC-Tg mice untreated or treated
with the PI3K𝛾 inhibitor AS-605240 (𝛽ENaC-Tg/AS-605240) or with vehicle (𝛽ENaC-Tg/Vehicle). Cells are expressed as number per mL
of BAL fluid. (a) ∗∗𝑃 < 0.01 WT/Vehicle versus 𝛽ENaC-Tg/Vehicle, ∗∗𝑃 < 0.01 𝛽ENaC-Tg/Vehicle versus 𝛽ENaC-Tg/AS-605240 and
∗
𝑃 < 0.05 WT/Vehicle versus PI3K𝛾WT/𝛽ENaC-Tg. (b) ∗∗𝑃 < 0.01 WT/Vehicle versus 𝛽ENaC-Tg/Vehicle and ∗𝑃 < 0.05 WT/Vehicle
versus PI3K𝛾WT/𝛽ENaC-Tg. (c). ∗∗𝑃 < 0.01WT/Vehicle versus 𝛽ENaC-Tg/Vehicle, ∗∗𝑃 < 0.01WT/Vehicle versus 𝛽ENaC-Tg/AS-605240,
and ∗𝑃 < 0.05WT/Vehicle versus PI3K𝛾WT/𝛽ENaC-Tg.
leukocyte recruitment is correlated with disease progression,
on the other hand increased susceptibility to infection might
be a potential side effect of the use of these molecules.
In this context, a previous study [54] showed that either
gene deletion or pharmacologic inhibition of PI3K𝛾 in mice
infected with S. pneumoniae caused an impaired exudate
macrophage recruitment associated with a reduced lung
pneumococcal clearance and an impaired resolution/repair
process, leading to progressive pneumococcal pneumonia.
Thus, whereas pharmacological inhibition of PI3K𝛾, even-
tually in association with antibacterial treatment, may be
a viable strategy to inhibit chronic inflammation and limit
lung damage in stable CF lung disease, it might have adverse
effects on host defense in acute infectionswhen high bacterial
8 Mediators of Inflammation
burden occurs. In view of a clinical application of PI3K𝛾
inhibitors, target validationwill be an important future aspect
to discriminate between specific effects of the drug and
potential side effects.
5. Conclusions
Neutrophil-dominated airway inflammation has been impli-
cated as a key feature of progressive lung damage in CF.Thus,
reducing airway inflammation is a major goal to prevent
lung damage and maintain lung function in CF. Current
therapeutic strategies that aim to reduce chronic neutrophilic
inflammation in the airways of CF patients have been largely
unsuccessful. This study shows that genetic deletion and
pharmacological inhibition of PI3K𝛾 decrease neutrophilic
airway inflammation and structural lung damage in a mouse
model of CF lung disease. These results provide insight into
the molecular mechanisms of chronic airway inflammation
and suggest a novel treatment strategy to reduce inflamma-
tion and lung damage in patients with CF and potentially
other neutrophilic airway diseases. Further studies with
emerging PI3K𝛾 inhibitors [49–51] are required to confirm
the efficacy of these molecules and exclude their potentially
adverse effects on host defense.
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